EP0145209A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
A kit or device and method for administering gangliosides and derivatives thereof of inhalation and pharmaceutical compositions suitable therefor
Assignee: Fidia SpA
•
Filing: 1984-10-26
•
Granted: —
•
Expires: 2004-10-26
Abstract
Abstract The present invention relates to a device or kit and a method for the inhalation administration of gangliosides and inner ester ganglioside derivatives useful for the treatment of various nervous disorders, such as those resulting from accidents or diseases which have damaged the nervous tissue.
Inventors
- 👤 Francesco Della Valle
- 👤 Aurelio Romeo
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-05 01:35
CPC Classifications
A; A61; A61K; A61K35/00; A61K35/12; A61K35/30; A61K9/00; A61K9/0012; A61K9/007; A61K9/0073; A61K9/008; A61K31/00; A61K31/70; A61P; A61P25/00; C; C07; C07H; C07H15/00; C07H15/02; C07H15/04; C07H15/10
Claims Analysis
Total Claims: 17
Claim 1
Independent Claim
148 words
A kit for inhalation administration of a pharmaceutical composition comprising: a spray device for inhalation administration; and a pharmaceutical composition comprising, (a) at least one ganglioside compound or a pharmaceutically acceptable salt thereof, or at least one inner ester ganglioside derivative or a pharmaceutically acceptable salt thereof, or mixtures thereof, wherein said inner ester ganglioside derivative comprises, (1) a carbohydrate portion, at least one ceramide and at least one acid moiety; (2) said carbohydrate portion including at least one N-acetylgalactosamine or N-acetylglucosamine moiety and at least one glucose or galactose moiety; (3) said acid moiety including at least one N-acetylneuraminic acid or N-glycolylneuraminic acid; and (4) the carboxyl group of at least one of said acid moieties being ester bonded to a hydroxyl group of one of said carbohydrates or one of said acid moieties to form a lactonic ring; and (b) a pharmaceutically acceptable carrier or diluent.
Claim 2
Dependent Claim
148 words
A kit for inhalation administration of a pharmaceutical composition comprising: a spray device for inhalation administration; and a pharmaceutical composition comprising, (a) at least one ganglioside compound or a pharmaceutically acceptable salt thereof, or at least one inner ester ganglioside derivative or a pharmaceutically acceptable salt thereof, or mixtures thereof, wherein said inner ester ganglioside derivative comprises, (1) a carbohydrate portion, at least one ceramide and at least one acid moiety; (2) said carbohydrate portion including at least one N-acetylgalactosamine or N-acetylglucosamine moiety and at least one glucose or galactose moiety; (3) said acid moiety including at least one N-acetylneuraminic acid or N-glycolylneuraminic acid; and (4) the carboxyl group of at least one of said acid moieties being ester bonded to a hydroxyl group of one of said carbohydrates or one of said acid moieties to form a lactonic ring; and (b) a pharmaceutically acceptable carrier or diluent.
Claim 3
Dependent Claim
16 words
A kit as claimed in Claim 1, wherein said spray device comprises a pressurized spray bottle.
Claim 4
Dependent Claim
16 words
A kit as claimed in Claim 1 or 2, wherein said composition further includes a bronchodilator.
Claim 5
Dependent Claim
12 words
A kit as claimed in Claim 3, wherein said bronchodilator is isoprenaline.
Claim 6
Dependent Claim
12 words
A kit as claimed in Claim 3, wherein said bronchodilator is adrenaline.
Claim 7
Dependent Claim
22 words
A kit as claimed in any one of the preceding Claims, wherein said composition is in the form of an atomized powder.
Claim 8
Dependent Claim
27 words
A kit as claimed in any one of Claims 1 to 5, wherein said composition is in the form of a nebulized liquified propellent suspension or solution.
Claim 9
Dependent Claim
50 words
A kit as claimed in any one of the preceding Claims, wherein in said inner ester ganglioside derivative each of said carboxyl groups of said acid moieties is ester bonded with a hydroxyl group of one of said carbohydrates or with one of said acid moieties to form lactonic rings.
Claim 10
Dependent Claim
21 words
A kit as claimed in any one of the preceding Claims, wherein said pharmaceutical composition is contained in said spray device.
Claim 11
Dependent Claim
135 words
A pharmaceutical composition comprising: (a) at least one ganglioside compound or a pharmaceutically acceptable salt thereof, or at least one inner ester ganglioside derivative or a pharmaceutically acceptable salt thereof, or mixtures thereof, wherein said inner ester ganglioside derivative comprises, (1) a carbohydrate portion, at least one ceramide and at least one acid moiety; (2) said carbohydrate portion including at least one N-acetylgalactosamine or N-acetylglucosamine moiety and at least one glucose or galactose moiety; (3) said acid moiety including at least one N-acetylneuraminic acid or N-glycolylneuramnic acid; and (4) the carboxyl group of at least one of said acid moieties being ester bonded to a hyroxyl group of one of said carbohydrates or one of said acid moietie: to form a lactonic ring; (b) a bronchodilator; and (c) a pharmaceuti( lly acceptable excipient or diluent.
Claim 12
Dependent Claim
135 words
A pharmaceutical composition comprising: (a) at least one ganglioside compound or a pharmaceutically acceptable salt thereof, or at least one inner ester ganglioside derivative or a pharmaceutically acceptable salt thereof, or mixtures thereof, wherein said inner ester ganglioside derivative comprises, (1) a carbohydrate portion, at least one ceramide and at least one acid moiety; (2) said carbohydrate portion including at least one N-acetylgalactosamine or N-acetylglucosamine moiety and at least one glucose or galactose moiety; (3) said acid moiety including at least one N-acetylneuraminic acid or N-glycolylneuramnic acid; and (4) the carboxyl group of at least one of said acid moieties being ester bonded to a hyroxyl group of one of said carbohydrates or one of said acid moietie: to form a lactonic ring; (b) a bronchodilator; and (c) a pharmaceuti( lly acceptable excipient or diluent.
Claim 13
Dependent Claim
14 words
A pharmaceutical composition as claimed in Claim 10, wherein said bronchodilator is imprenaline sulfate.
Claim 14
Dependent Claim
13 words
A pharmaceutical composition as claimed in Claim 10, wherein said bronchodilator is adrenaline.
Claim 15
Dependent Claim
16 words
A pharmaceutical composition as claimed in Claim 10, 11 or 12, wherein said excipient is lactose.
Claim 16
Dependent Claim
52 words
A pharmaceutical composition as claimed in any one of Claims 10 to 13, wherein in said inner ester ganglioside derivative each of said carboxyl groups of said acid moieties is ester bonded with a hydroxyl group of one of said carbohydrates or with one of said acid moieties to form lactonic rings.
Claim 17
Dependent Claim
138 words
An inner ester ganglioside derivative or a pharmaceutically acceptable salt thereof, or mixtures thereof, the inner ester ganglioside derivative comprising: (a) a carbohydrate portion, at least one ceramide and at least one acid moiety; (b) said carbohydrate portion including at least one N-acetylgalactosamine or N-acetylglucosamine moiety and at least one glucose or galactose moiety; (c) said acid moiety including at least one N-acetylneuraminic acid or N-glycoiylneuraminic acid; and (d) the carboxyl group of at least one of said acid moieties being ester bonded to a hydroxyl group of one of said carbohydrates or one of said acid moieties to form a lactonic ring, for use as a medicament. 16. An inner ester ganglioside derivative or a pharmaceutically acceptable salt thereof, or mixtures thereof as claimed in Claim 15 for use in the treatment of disorders of nervous system.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.